Fluoxetine

Generic Name: Fluoxetine

Brand Names: Prozac, Sarafem, Symbyax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈F_₃NO

CAS Number: 54910-89-3

Unique Ingredient Identifier: 01K63SUP8D

Background: Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication: Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).

Associated Conditions: Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)

Associated Therapies: Maintenance therapy

Clinical Trials

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Atilotrelvir/ritonavir
Drug: Nirmatrelvir/ritonavir
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Nitazoxanide
Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Hydroxychloroquine
Other: No treatment
Drug: Monoclonal antibodies
Drug: Fluoxetine
Drug: Molnupiravir
Drug: Sotrovimab
Drug: Ensitrelvir
Drug: Favipiravir
Drug: Ivermectin
Drug: Remdesivir
Drug: Metformin
Drug: Nirmatrelvir

First Posted Date: 2021-09-13

Last Posted Date: 2024-10-28

Lead Sponsor: University of Oxford

Target Recruit Count: 3800

Registration Number: NCT05041907

Locations: 🇳🇵
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦
Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Phase 2

Conditions: Covid19
Covid19 Drug Treatment
SARS-CoV2 Infection
Severe Acute Respiratory Syndrome Coronavirus 2

Interventions: Drug: Nitazoxanide and Ciclésonide
Drug: Telmisartan 20Mg Oral Tablet
Drug: Fluoxétine and Budésonide
Drug: Paracetamol

First Posted Date: 2021-06-10

Last Posted Date: 2023-01-31

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 600

Registration Number: NCT04920838

Locations: 🇬🇳
Centre de traitement des maladies à tendance épidémique de Gbessia, Conakry, Guinea
🇧🇫
Centre Muraz/INSP, Bobo-Dioulasso, Burkina Faso

Study of Dextromethorphan in OCD and Related Disorders

Phase 2

Recruiting

Conditions: Body Dysmorphic Disorders
Somatic Symptom Disorder
Obsessive-Compulsive Disorder
Illness Anxiety Disorder

Interventions: Drug: Fluoxetine
Drug: Dextromethorphan

First Posted Date: 2021-05-24

Last Posted Date: 2024-04-26

Lead Sponsor: Stanford University

Target Recruit Count: 60

Registration Number: NCT04899687

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma

Phase 2

Active, not recruiting

Conditions: Musculoskeletal Injury

Interventions: Drug: Fluoxetine
Drug: Calcium

First Posted Date: 2021-04-20

Last Posted Date: 2025-01-23

Lead Sponsor: University of Florida

Target Recruit Count: 150

Registration Number: NCT04850222

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic

Phase 2

Conditions: Major Depressive Disorder

Interventions: Device: Transcranial Direct Current Stimulation
Device: Placebo-simulation of transcranial direct current stimulation
Drug: Fluoxetine Tablets

First Posted Date: 2021-03-03

Last Posted Date: 2021-06-04

Lead Sponsor: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

Target Recruit Count: 172

Registration Number: NCT04780152

Locations: 🇲🇽
Instituto Nacional de Neurología y Neurocirugía, Mexico City, Ciudad De México, Mexico

Fluoxetine vs CBT in Childhood Anxiety Disorders

Phase 3

Active, not recruiting

Conditions: Anxiety Disorders

Interventions: Behavioral: Cognitive Behavioral Therapy (CBT)
Drug: Fluoxetine

First Posted Date: 2021-02-18

Last Posted Date: 2025-04-11

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 316

Registration Number: NCT04760275

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Phase 3

Recruiting

Conditions: Covid19
SARS-Associated Coronavirus

Interventions: Dietary Supplement: Spirulin Platensis
Drug: Fluoxetine 20 MG
Drug: Budesonide Powder
Drug: Placebo

First Posted Date: 2021-01-27

Last Posted Date: 2024-05-08

Lead Sponsor: Cardresearch

Target Recruit Count: 7819

Registration Number: NCT04727424

Locations: 🇧🇷
City of Governador Valadares, Governador Valadares, MG, Brazil
🇧🇷
Centro Universitário FIPMOC, Montes Claros, Minas Gerais, Brazil
🇧🇷
City of Betim, Betim, MG, Brazil

and more 9 locations